Paradigm Biopharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Paradigm Biopharmaceuticals's earnings have been declining at an average annual rate of -33.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 69.6% per year.
Key information
-33.4%
Earnings growth rate
-21.3%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -69.6% |
Return on equity | -204.1% |
Net Margin | -164,092.7% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Paradigm Biopharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -69 | 6 | 71 |
30 Sep 23 | 0 | -60 | 7 | 62 |
30 Jun 23 | 0 | -52 | 7 | 53 |
31 Mar 23 | 0 | -48 | 9 | 48 |
31 Dec 22 | 0 | -44 | 10 | 43 |
30 Sep 22 | 0 | -42 | 9 | 41 |
30 Jun 22 | 0 | -39 | 9 | 39 |
31 Mar 22 | 0 | -40 | 9 | 39 |
31 Dec 21 | 0 | -41 | 10 | 40 |
30 Sep 21 | 0 | -37 | 10 | 37 |
30 Jun 21 | 0 | -34 | 10 | 34 |
31 Mar 21 | 0 | -31 | 7 | 30 |
31 Dec 20 | -1 | -28 | 5 | 27 |
30 Sep 20 | 0 | -20 | 4 | 20 |
30 Jun 20 | 0 | -12 | 3 | 14 |
31 Mar 20 | 2 | -14 | 4 | 12 |
31 Dec 19 | 4 | -16 | 4 | 9 |
30 Sep 19 | 3 | -16 | 4 | 8 |
30 Jun 19 | 3 | -16 | 4 | 8 |
31 Mar 19 | 3 | -11 | 3 | 7 |
31 Dec 18 | 3 | -7 | 3 | 7 |
30 Sep 18 | 3 | -7 | 2 | 7 |
30 Jun 18 | 3 | -6 | 2 | 7 |
31 Mar 18 | 2 | -6 | 2 | 6 |
31 Dec 17 | 2 | -5 | 2 | 5 |
30 Sep 17 | 2 | -5 | 2 | 5 |
30 Jun 17 | 2 | -4 | 2 | 4 |
31 Mar 17 | 2 | -4 | 2 | 4 |
31 Dec 16 | 1 | -4 | 2 | 4 |
30 Sep 16 | 1 | -4 | 2 | 3 |
30 Jun 16 | 1 | -3 | 1 | 3 |
31 Mar 16 | 1 | -3 | 2 | 2 |
31 Dec 15 | 0 | -2 | 1 | 1 |
30 Sep 15 | 0 | -2 | 1 | 1 |
30 Jun 15 | 0 | -2 | 1 | 0 |
Quality Earnings: PBIG.F is currently unprofitable.
Growing Profit Margin: PBIG.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PBIG.F is unprofitable, and losses have increased over the past 5 years at a rate of 33.4% per year.
Accelerating Growth: Unable to compare PBIG.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PBIG.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: PBIG.F has a negative Return on Equity (-204.15%), as it is currently unprofitable.